Logo

BioMerieux, ExonHit to Develop Dx to Help Predict Surgery Risk in Prostate Cancer

Jan 05, 2007
NEW YORK (GenomeWeb News) — BioMérieux and ExonHit Therapeutics plan to develop a blood-based prostate-cancer screening test aimed at helping doctors weigh the risks of performing surgery to remove tumors, BioMérieux said yesterday.
 
Under the collaboration, BioMérieux will use ExonHit’s genome expression IP to develop DNA chips that can detect “several dozens of nucleic acid markers” and use them to find cancer markers in blood.
 
Financial terms of the agreement were not released.
 
The two companies also are involved in a study for a blood-based breast cancer diagnostic and a similar program to develop a test to detect colorectal cancer.

Filed under

Microarrays & Multiplexing
microarrays
Breaking News
The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.